Globotriaosylceramide Immunostaining of Myocardium in a Patient With Fabry Disease

Circ J. 2022 Aug 25;86(9):1479. doi: 10.1253/circj.CJ-22-0067. Epub 2022 Mar 25.

Authors

Satoru Yoshida¹, Hiroaki Kawano¹, Satoshi Ikeda¹, Hitoshi Sakuraba², Shinji Okano³, Koji Maemura¹

Affiliations

¹ Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences.
² Department of Clinical Genetics, Meiji Pharmaceutical University.
³ Department of Pathology, Nagasaki University Hospital.

PMID: 35342148
DOI: 10.1253/circj.CJ-22-0067

No abstract available

MeSH terms

Fabry Disease* / complications
Humans
Myocardium
Trihexosylceramides
alpha-Galactosidase

Substances

Trihexosylceramides
globotriaosylceramide
alpha-Galactosidase